Last reviewed · How we verify

Tertiary lesion of yaws — Treatment Landscape & Competitive Intelligence

Tertiary lesion of yaws (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Tertiary lesion of yaws, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Penicillin G Potassium In Plastic Container Benzylpenicillin Pfizer Penicillin-class Antibacterial 1947-01-01
penicillin penicillin Karlstad University Bacterial penicillin-binding protein, Beta-lactamase, Beta-lactamase TEM

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Karlstad University · 1 drug in Tertiary lesion of yaws
  2. Pfizer · 1 drug in Tertiary lesion of yaws

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Tertiary lesion of yaws:

Cite this brief

Drug Landscape (2026). Tertiary lesion of yaws — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/tertiary-lesion-of-yaws. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing